Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Warrants B have a Buy Signal recommendation

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Aug 20, 2021 6:17pm

279 Views

Post# 33743972

RE:RE:RE:RE:RE:Warrants B have a Buy Signal recommendation

Red~One wrote: That's the problem I have heard various opinions on how the new formula works.

T

It's very simple:
>>Before the split
   *1 warrant gets you 1 share
   *the exercise price of the warrant is 6.5 cents

>>After the split
   *shares are consolidated 20:1
   *warrants are not consolidated
   *exercise price of the warrant is still 6.5 cents
   *20 warrants get you 1 share

So, you have to exercise 20 warrants and pay 20x0.065=$1.30 to get 1 share

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks